Cellectar Biosciences (CLRB) Misses Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. SPY
3. PTC
4. META
5. PCVX
6. USO
7. MSFT
8. AMZN
9. AMD
10. ATH

Go back to Cellectar Biosciences (CLRB) Misses Q1 EPS by 1c

Cellectar Biosciences (CLRB) Says it Was Granted FDA Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma

May 9, 2018 2:29 PM EDT

Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to... More